Method for designing lung-targeting polypeptide sequence, and polypeptide-modified liposome for targeted delivery of drug

By designing peptide-modified liposomes and optimizing the binding strength between the peptide sequence and polinecin using molecular mechanics calculations, the problem of targeted delivery of liposomes to extrahepatic organs has been solved, achieving efficient drug delivery to specific organs and tissues, providing criteria for lung targeting, and possessing universality and reproducibility.

WO2026233322A1PCT designated stage Publication Date: 2026-11-12TSINGHUA UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/094958
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing liposome delivery vectors are difficult to target for extrahepatic organs or tissues, and traditional methods lack modular control characteristics, resulting in low in vivo delivery efficiency of nucleic acid drugs.

Method used

A peptide-modified liposome was designed, and the binding strength between the peptide sequence and polinecin was optimized through molecular mechanics calculations to achieve lung-targeted delivery. The specific steps include peptide synthesis, coupling, liposome preparation and microfluidic blending to form lung-targeting nanoliposomes.

Benefits of technology

It achieves targeted drug delivery to specific organs, tissues and cells, has a certain degree of universality, can preferentially accumulate in extrahepatic organs such as placenta, bone marrow, adipose tissue or testes, provides lung targeting threshold criteria, and the calculation method is repeatable and universal.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2026094958-FTAPPB-I100001
    Figure PCTCN2026094958-FTAPPB-I100001
  • Figure PCTCN2026094958-FTAPPB-I100002
    Figure PCTCN2026094958-FTAPPB-I100002
  • Figure PCTCN2026094958-FTAPPB-I100003
    Figure PCTCN2026094958-FTAPPB-I100003
Patent Text Reader

Abstract

A polypeptide-modified liposome for targeted delivery of a drug and the use thereof, relating to the technical field of biomedicine. Starting materials for preparing the liposome comprise a polypeptide-modified lipid material, the polypeptide-modified lipid material being obtained by coupling a polypeptide to a lipid material that contains a polyethylene glycol chain. The polypeptide is CYS-(X)N, wherein X is any one or any two of LYS, HIS or ARG, N is the total number of X and is an integer greater than 1 and less than 11, and the polypeptide is coupled to the polyethylene glycol chain by means of a thiol group on a cysteine residue thereof. Also provided are a method for designing an organ-targeting polypeptide sequence, specifically a method for designing a lung-targeting polypeptide sequence on the basis of molecular-binding strength, the use of same, and the lung-targeting polypeptide sequence. The polypeptide can perform surface modification on nanoliposomes, and thus is applied to lung-targeted delivery of nucleic acid drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Lung-targeting peptide sequence design method and peptide-modified liposomes for targeted drug delivery Technical Field

[0001] This application relates to the field of biomedical technology, and in particular to a lung-targeting polypeptide and polypeptide-modified liposomes for targeted drug delivery and their applications. Background Technology

[0002] Currently, mRNA vaccines are widely used. Their successful application is not only a milestone in the vaccine field, but it has also greatly promoted the development of nucleic acid drugs in various fields, such as tumor immunotherapy, tissue regeneration and repair, cell fate regulation, and gene editing. In principle, nucleic acid drugs, due to their modular preparation characteristics, can rapidly produce mRNA or DNA sequences based on target proteins, and then deliver them to target organs or tissues in vivo using specific nucleic acid delivery vectors. Therefore, nucleic acid drugs possess the advantages of personalization, standardization, and modularity, giving them enormous potential for rapid and widespread application.

[0003] However, due to the instability and targeting limitations of naked nucleic acid drugs (mRNA, siRNA, and DNA, etc.) caused by various factors within the body, it is difficult for them to be actively delivered to specific target sites to exert their effects. Therefore, nucleic acid drugs must rely on specific delivery carriers. These carriers not only protect the encapsulated nucleic acid drugs from degradation by nucleases but also deliver them to specific tissues, organs, or even cell types through their targeting capabilities, thus achieving targeted delivery. Therefore, safe, efficient, and targeted delivery carriers are crucial for nucleic acid drugs to truly function in vivo. Because of the presence of multiple biochemical and physical barriers in the body, once nucleic acid drugs enter the body, various mechanisms such as blood flow shearing, protein coronal coating, the mononuclear phagocyte system, and nucleic acid-degrading enzymes can cause them to become ineffective before reaching specific target cells. After being endocytosed by cells, nucleic acid drugs need to escape from endosomes, which further limits their delivery efficiency. Therefore, successfully delivering nucleic acid drugs to specific sites in vivo is extremely challenging. Currently, inorganic nanomaterials, peptides, polymers, and liposomes (LNPs) have all been developed as nucleic acid drug delivery carriers. Among these carriers, liposomes, as delivery carriers for nucleic acids, proteins, and chemical drugs, have been widely used in numerous fields such as COVID-19 vaccines, cancer immunotherapy, and tissue repair and regeneration. For example, in the field of liver disease treatment, Onpattro, a product approved by the FDA in August 2018, is widely used clinically. This product is an LNP formulation carrying siRNA, used to treat polyneuropathy caused by the hereditary disease transthyretin-mediated amyloidosis (hATTR), exerting its effect by inhibiting the synthesis of hepatic thyroxine transporter (TTR). Currently, the liver is the primary target organ for widely used liposome-carrier drugs. Overcoming the liver's barrier is crucial for these drugs to achieve their intended effect.

[0004] To achieve targeted delivery to extrahepatic organs, there are currently three main approaches: (1) Changing the delivery method by delivering drugs to specific sites via local injection, thereby avoiding the multiple barriers encountered by nucleic acid drugs via systemic intravenous injection in vivo, and thus enabling targeted drug delivery to specific tissue sites; (2) Construction and screening of liposome chemical libraries: Researchers currently mainly construct nano-libraries by modifying the chemical structure of ionized liposomes, and then screen organ-targeting carriers through high-throughput screening; (3) Addition of additional components: Researchers add a fifth component to the original four components of liposomes, and through the regulation of the charge properties of the added components, targeted delivery to extrahepatic organs can be achieved. In summary, organ-targeting carriers administered intravenously, whether through chemical library design and charge modulation, only optimize the chemical structure or properties of liposomes from the perspective of chemical structure and composition, thereby altering their in vivo targeted delivery behavior. However, the carriers designed by this method obviously lack modular control characteristics. In contrast, peptide nanocarriers with coded properties have advantages such as excellent biocompatibility, rich structure, and diverse functions. Therefore, combining peptide-modified nanoliposomes is of great significance for screening, optimizing, and designing multi-scale targeted nanocarriers for organs, tissues, and cells in vivo.

[0005] Based on research on the regulation of organ selectivity of LNPs by the protein corona adsorbed on their surface, the applicant hopes to guide the delivery of peptide-modified LNPs to the lungs through the active and rational design of peptide sequences with excellent binding strength to the lung-targeting key protein vitronectin (Vtn). Summary of the Invention

[0006] The purpose of this application is to provide a peptide-modified liposome for targeted drug delivery and its application, thereby addressing the problems existing in the prior art. Furthermore, based on molecular mechanics design criteria and through methods such as molecular dynamics calculations, a peptide sequence with high affinity for Vtn is designed to guide LNP for lung-targeted delivery. The specific technical solution is as follows.

[0007] One aspect of this application proposes a peptide-modified liposome for organ-targeted drug delivery. First, a peptide is formed by dehydration condensation of different types and numbers of amino acids. Then, the prepared peptide is coupled to Mal-PEG. 2k -DSPE involves dissolving five components of liposomes in an alcohol phase and nucleic acids in an aqueous phase, then microfluidically blending the two to form nucleic acid-encapsulated nanoliposomes. Injecting these nucleic acid-encapsulated nanoliposomes into mice enables targeted delivery to specific organs. Specifically, this application involves the following operations and studies:

[0008] S1, Peptide Preparation

[0009] Select specific types and numbers of amino acids or amino acid derivatives according to experimental requirements, and prepare specific encoded peptides using peptide synthesis (e.g., Fmoc solid-phase peptide synthesis method). The type and length of the peptide depend on the type and number of amino acids or amino acid derivatives input (computer-aided design). By controlling the properties of the prepared peptide (charge, hydrophobic interaction, hydrogen bonding, etc.), targeted drug delivery to specific organs, tissues, and cells in the body can be achieved.

[0010] S2, Preparation of peptide-modified liposomes

[0011] A cysteine ​​residue is introduced at the terminal (C-terminus or N-terminus) of the peptide to participate in the reaction, utilizing the thiol group of the cysteine ​​to react with Mal-PEG. 2k -DSPE reaction can couple the peptide synthesized in step S1 to PEG. 2k -DSPE surface, and finally its chemical structure was analyzed by 1H NMR spectroscopy to confirm successful peptide coupling to PEG. 2k -DSPE surface. Then, a certain proportion of ionized lipids (such as SM102), cholesterol, phospholipids (such as DSPC), and peptide-conjugated PEG are dissolved in ethanol, and a specific amount of nucleic acid (such as mRNA) is dissolved in citrate buffer. Then, the aqueous phase and the alcohol phase are mixed at a specific flow rate using a microfluidic device. During the microfluidic mixing process, the nucleic acid and lipid components self-assemble to achieve the preparation of peptide-modified liposomes.

[0012] S3. Peptide-modified liposomes enable organ-targeted delivery of mRNA in vivo.

[0013] A certain amount of the liposomes synthesized in step S3 was injected intravenously / intraperitoneally into mice. To determine the organ distribution of the peptide-modified liposomes in vivo, the nucleic acid was encapsulated using mRNA encoding green fluorescent protein (EGFP mRNA). Several hours after injection of the mouse liposomes, in vivo imaging was performed on various mouse organs under the action of the substrate to observe and identify the target organs for mRNA delivery.

[0014] Based on the above research, the present invention provides the following solution:

[0015] This application provides a polypeptide-modified lipid material, which is obtained by coupling a polypeptide to a lipid material containing polyethylene glycol chains;

[0016] The polypeptide is Cys-(X). n Where X is any one or both of Lys or His, and n is the total number of X and is an integer in the range of greater than 1 and less than 11;

[0017] The polypeptide is coupled to the polyethylene glycol chain via a thiol group on its cysteine ​​residue.

[0018] Furthermore, all or all of the n X's in the polypeptide are Lys.

[0019] Furthermore, when some of the n X's are Lys, the remaining X's are Arg.

[0020] Furthermore, all n X's in the polypeptide are His.

[0021] Further, n in the polypeptide is 2, 3, 4, 5, 6, 7, 8 or 10. More preferably, n is 3, 4, 5, 6, 7 or 8.

[0022] Furthermore, the polypeptide-modified lipid material containing polyethylene glycol chains is Mal-PEG. 2k -DSPE.

[0023] This application also provides the use of the peptide-modified lipid materials described above in the preparation of peptide-modified liposomes for targeted drug delivery.

[0024] Furthermore, the peptide-modified liposomes used for targeted drug delivery target organs in vivo.

[0025] Furthermore, the internal organs are the placenta, bone marrow, testes, and / or adipose tissue.

[0026] This application also provides a peptide-modified liposome for targeted drug delivery, the raw materials for which are prepared, including the peptide-modified lipid materials described above.

[0027] Furthermore, the polypeptide-modified liposomes also include ionized lipids, phospholipids, cholesterol, and phospholipid-polyethylene glycol.

[0028] Further, the molar ratio of the ionized lipid, the phospholipid, the cholesterol, the polypeptide-modified lipid material, and the phospholipid-polyethylene glycol is (40-60):(5-15):(30-45):(3-12):(0.5-1.5).

[0029] Further, the phospholipid is distearylphosphatidylcholine, 1,2-dioleoyl-SN-glycerol-3-phosphocholine, 1,2-dioleoylpropanetriyl-3-phosphatidylethanolamine, hydrogenated soybean phosphatidylcholine, or lecithin.

[0030] Furthermore, the ionized lipid is MC3, SM102, ALC0315, or LP01.

[0031] This application also provides the application of the peptide-modified lipid materials or peptide-modified liposomes described above in improving drug targeting.

[0032] This application also provides the use of the aforementioned peptide-modified lipid materials or peptide-modified liposomes in the preparation of drugs targeting organs in vivo. Further, the organs in vivo are the placenta, bone marrow, testes, and / or adipose tissue.

[0033] This application also provides a method for improving drug targeting, which includes using the peptide-modified lipid material or peptide-modified liposomes described above.

[0034] Another aspect of this application provides a lung-targeting polypeptide sequence, wherein the energy relationship between the polypeptide sequence and vilinkin (Vtn) satisfies the following condition:

[0035] and / or

[0036] Combined free energy (ΔG) BIND <30 kcal / mol

[0037] Wherein, the energy release rate (G) is the cleavage energy at the interface between the polypeptide sequence and glassin, and the binding free energy (ΔG) is... BIND The molecular mechanical energy (G) between the polypeptide and glassin is... GAS ) and solvation energy (G SOLV ) and.

[0038] Furthermore, the energy release rate (G) is the ratio of the mechanical work (W) of the polypeptide sequence and glassin in the molecular dynamics model to the nominal contact area (S).

[0039] Furthermore, the nominal contact area (S) is obtained by the following formula:

[0040] S = n × L × b,

[0041] Where n is the number of amino acids contained in the polypeptide sequence, L is the average length of each amino acid in the polypeptide sequence, and b is the average width of each amino acid in the polypeptide sequence.

[0042] Furthermore, n is a natural number. More preferably, n is selected from 3, 4, 5, 6, 7, 8, 9, 10, or 11.

[0043] Furthermore, the mechanical work (W) is obtained as follows:

[0044] A stretching molecular dynamics model of the peptide sequence and polinecin was established. In the complex structure in which the peptide and the target protein are bound, the peptide is stretched along the vector direction of the peptide at a constant rate of 1 nm / ns. The vector direction of the peptide is defined as the direction of the line connecting the terminal amino acid of the peptide away from the binding pocket to the α-carbon atom coordinate of the starting amino acid at the other end. The area under the force-stretching curve within the displacement range of the peptide being pulled out of the complex structure is calculated by integral calculation, which is the mechanical work (W).

[0045] Furthermore, the molecular mechanical energy (G) GAS It is derived from the following formula:

[0046] G GAS =G BOND +G ANGLE +G DIHED +G VDWAALS +G EEL ,in,

[0047] G BOND =ΣK b (b-b0) 2 G ANGLE =ΣK θ (θ-θ0) 2 G DIHED =ΣK χ (1-cos(nχ-δ)), G VDWAALS =Σε[(R min / r ij ) 12 -(R min / r ij ) 6 ], G EEL =Σq i q j / ε1r ij ,

[0048] b is the covalent bond length, b0 is the equilibrium value, θ is the covalent bond angle, θ0 is the equilibrium value, χ is the dihedral angle, n is the dihedral angle period, δ is the phase angle, and K b K θ K χ R is the force constant, ε is the depth of the Lennard-Jones potential well, and R is the force constant. min r is the distance at the minimum of the Lennard-Jones potential. ij q is the distance between atoms i and j. i q j ε is the atomic charge, and ε1 is the effective dielectric constant.

[0049] Furthermore, the solvation energy (G) SOLV ) is the polar solvation energy (EPB ) and nonpolar solvation energy (E SURF ) and.

[0050] Furthermore, the polar solvation energy (E) PB The nonpolar solvation energy (E) was calculated using the Poisson-Boltzmann method. SURF )=γ·SASA+β.

[0051] Furthermore, the polypeptide sequence is RRRRRR (Seq ID No. 1) or RRRYRR (Seq ID No. 2).

[0052] This application also provides a peptide-modified lipid material with lung-targeting properties, wherein the peptide-modified lipid material is obtained by coupling a peptide to a lipid material containing a polyethylene glycol chain;

[0053] The polypeptide comprises the polypeptide sequence described above.

[0054] Furthermore, one end of the polypeptide is a cysteine ​​residue (Cys), which is coupled to the polyethylene glycol chain.

[0055] Further, the polypeptide is Cys-X, where X is the lung-targeting polypeptide sequence described above. Further, the lipid material containing the polyethylene glycol chain is Mal-PEG. 2k -DSPE.

[0056] This application also provides a peptide-modified liposome for targeted drug delivery, the raw materials for which are prepared, including the peptide-modified lipid materials described above.

[0057] Furthermore, the raw materials for preparing the polypeptide-modified liposomes also include ionized lipids, phospholipids, cholesterol, and phospholipid-polyethylene glycol.

[0058] Further, the molar ratio of the ionized lipid, the phospholipid, the cholesterol, the polypeptide-modified lipid material, and the phospholipid-polyethylene glycol is (40-60):(5-15):(30-45):(3-12):(0.5-1.5).

[0059] Further, the phospholipid is distearylphosphatidylcholine, 1,2-dioleoyl-SN-glycerol-3-phosphocholine, 1,2-dioleoylpropanetriyl-3-phosphatidylethanolamine, hydrogenated soybean phosphatidylcholine, or lecithin.

[0060] Furthermore, the ionized lipid is MC3, SM102, ALC0315, or LP01.

[0061] This application also provides the use of the above-described polypeptide sequences or polypeptide-modified lipid materials or polypeptide-modified liposomes in the preparation of lung-targeted drug delivery.

[0062] This application also provides the application of the above-described polypeptide sequences or polypeptide-modified lipid materials or polypeptide-modified liposomes in improving drug lung targeting.

[0063] This application also provides a method for improving drug lung targeting, which includes using the above-described polypeptide sequence or polypeptide-modified lipid material or polypeptide-modified liposome.

[0064] This application also provides a method for screening organ-targeting polypeptide sequences, including:

[0065] The energy relationship between the target polypeptide sequence and the target protein that mediates organ targeting is obtained, and the energy relationship is used to determine whether the target polypeptide sequence has organ targeting specificity.

[0066] Wherein, the energy relationship refers to the cleavage energy at the binding interface between the target polypeptide sequence and the target protein, expressed as energy release rate (G), and / or the molecular mechanical energy (G0) between the target polypeptide sequence and the target protein. GAS ) and solvation energy (G SOLV The sum of ) to combine the free energy (ΔG) BIND )express.

[0067] Furthermore, the energy relationship between the target polypeptide sequence and the target protein mediating organ targeting is obtained. Based on the energy relationship, the target polypeptide sequence is considered to have organ targeting ability if the following conditions are met:

[0068] and / or

[0069] Combined free energy (ΔG) BIND < -30 kcal / mol.

[0070] More preferably, the organ is the lung, and the target protein is vitrin (Vtn).

[0071] Furthermore, the energy release rate (G) is the ratio of the mechanical work (W) of the polypeptide sequence and the target protein in the molecular dynamics model to the nominal contact area (S).

[0072] Furthermore, the mechanical work (W) is obtained as follows:

[0073] In the complex structure in which the peptide binds to the target protein, the peptide is stretched along its vector direction at a constant rate of 1 nm / ns. The vector direction of the peptide is defined as the direction of the line connecting the terminal amino acid at the end far from the binding pocket and the starting amino acid at the other end. The area under the force-stretch curve within the displacement range of the peptide being pulled out of the complex structure is calculated by integral and is the mechanical work (W).

[0074] Furthermore, the nominal contact area (S) is obtained by the following formula:

[0075] S = n × L × b,

[0076] Where n is the number of amino acids contained in the polypeptide sequence, L is the average length of each amino acid in the polypeptide sequence, and b is the average width of each amino acid in the polypeptide sequence.

[0077] Furthermore, n is selected from 3, 4, 5, 6, 7, or 8.

[0078] Furthermore, the molecular mechanical energy (G) GAS It is derived from the following formula:

[0079] G GAS =G BOND +G ANGLE +G DIHED +G VDWAALS +G EEL ,in,

[0080] G BOND =ΣK b (b-b0) 2 G ANGLE =ΣK θ (θ-θ0) 2 G DIHED =ΣK χ (1-cos(nχ-δ)), G VDWAALS =Σε[(R min / r ij ) 12 -(R min / r ij ) 6 ], G EEL =Σq i q j / ε1r ij ,

[0081] b is the covalent bond length, b0 is the equilibrium value, θ is the covalent bond angle, θ0 is the equilibrium value, χ is the dihedral angle, n is the dihedral angle period, δ is the phase angle, and K b K θ K χR is the force constant, ε is the depth of the Lennard-Jones potential well, and R is the force constant. min r is the distance at the minimum of the Lennard-Jones potential. ij q is the distance between atoms i and j. i q j ε is the atomic charge, and ε1 is the effective dielectric constant.

[0082] Furthermore, the solvation energy (G) SOLV ) is the polar solvation energy (E PB ) and nonpolar solvation energy (E SURF The sum of the polar solvation energies (E) PB The nonpolar solvation energy (E) was calculated using the Poisson-Boltzmann method. SURF )=γ·SASA+β.

[0083] The effects of the invention

[0084] This application has the following technical advantages:

[0085] 1. The peptide-modified liposomes provided in this application can achieve targeted drug delivery to specific organs, tissues and cells in vivo.

[0086] 2. This application has a certain degree of universality and can be used in combination with a variety of commercially available liposome excipients. The types of ionized lipid materials and phospholipids can be adjusted arbitrarily. Peptide-modified liposomes can preferentially accumulate in specific organs or tissues other than the liver, spleen, and lungs, such as the placenta, bone marrow, adipose tissue, or testes.

[0087] 3. This application clarifies the threshold of lung-targeting peptides through quantitative design. or Δ GBIND <-30 kcal / mol), where the energy release rate (G) focuses on mechanical stability, and the binding free energy (Δ) GBIND Reflecting thermodynamic intensity, the two criteria are independent and valid. Satisfying either one is sufficient to determine lung targeting, providing a direct basis for the rational design of lung-targeting LNPs.

[0088] 4. The calculations and judgments were performed using two widely validated and commonly used molecular dynamics simulation software programs, NAMD and GROMACS. This theoretical method is repeatable and universal.

[0089] 5. Liposome modification using the peptides involved and screened in this application can achieve targeted drug delivery to lung organs, tissues or cells. Attached Figure Description

[0090] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0091] Figure 1 shows the chemical structures of the synthesized polypeptides 6H(a), 6K(b), and 8K(c) prepared in Example 1.

[0092] Figure 2 shows the characterization of DSPE-PEG. 2k -6H / 6K / 8K 1H NMR spectrum results.

[0093] Figure 3 is a schematic diagram of a microfluidic device for preparing liposomes modified with mRNA peptides.

[0094] Figure 4 shows in vivo imaging of various organs after EGFP mRNA was delivered using 6K-3-LNP, TLNP, and PBS, respectively.

[0095] Figure 5 shows the statistical results of fluorescence of expressed proteins in various organs (from left to right: placenta, spleen, liver, lung, and spleen).

[0096] Figure 6 shows the percentage of mRNA-expressed proteins delivered to each organ (from top to bottom: placenta, spleen, lung, and liver).

[0097] Figure 7 shows in vivo imaging images using ESM-6H-LNP, ESM-TLNP, and PBS, respectively.

[0098] Figure 8 shows the statistical results of fluorescence of expressed proteins in various organs (from left to right: bone marrow, liver, lung, and spleen).

[0099] Figure 9 shows the percentage of mRNA-expressed proteins delivered to each organ (from top to bottom: bone marrow, spleen, lung, and liver).

[0100] Figure 10 shows in vivo imaging using 8K-LNP, TLNP, and PBS, respectively.

[0101] Figure 11 shows the statistical results of fluorescence of expressed proteins in various organs (from left to right: adipose tissue, liver, lung, and spleen).

[0102] Figure 12 shows the percentage of mRNA-expressed proteins delivered to each organ (from top to bottom: adipose tissue, spleen, lung, and liver).

[0103] Figure 13 shows in vivo imaging using 6K-LNP, TLNP, and PBS, respectively.

[0104] Figure 14 shows the statistical results of fluorescence of expressed proteins in various organs (from left to right: testis, liver, lung, and spleen).

[0105] Figure 15 shows the percentage of mRNA-expressed proteins delivered to each organ (from top to bottom: testis, spleen, lung, and liver).

[0106] Figure 16 shows a flow cytometry gating diagram of placental-targeted LNP delivery to trophoblast cells.

[0107] Figure 17 is a gate diagram of bone marrow-targeted LNP delivery to long-term hematopoietic stem cells (LT-HSC) and multi-lineage reconstitution of LT-HSC.

[0108] Figure 18 is a gate diagram of flow cytometry for targeted LNP delivery to adipocyte progenitor cells in adipose tissue.

[0109] Figure 19 is a gate diagram of testicular-targeted LNP delivery to testicular spermatogonia and spermatogonial stem cells.

[0110] Figure 20 shows the percentage of parenchymal cells in different target organs (a: placenta; b: bone marrow; c: adipose tissue; d: testis) in a quantitative analysis.

[0111] Figure 21 shows the force-tension curves within the displacement range of 0-4 nm during the G-value calculation process in Example 4.

[0112] Figure 22 shows the calculated G values ​​for each sequence of 4R / 5R / 6R / 7R / 8R in Example 4.

[0113] Figure 23 shows the workflow for designing lung-targeting peptides based on the affinity between peptides and Vtn.

[0114] Figure 24 shows the configuration of polypeptide-Vtn complexes with different peptide sequences generated by AlphaFold3.

[0115] Figure 25 shows the 1H NMR characterization results of the peptide-modified lipid material in Example 6.1.

[0116] Figure 26 shows the luciferase expression levels in the liver, lung, spleen, heart, and kidney of mice after delivery of luciferase (Luc) mRNA using RRRRRR-LNP, RRERRR-LNP, and RRRYRR-LNP in vitro.

[0117] Figure 27 shows the quantitative analysis results of luminescence intensity in the liver, lung, and spleen of mice after delivery of Luc mRNA using RRRRR-LNP, RRRERRR-LNP, and RRRYRR-LNP.

[0118] Figure 28 is a stacked bar chart showing the relative expression levels of luciferase in the liver, lung, and spleen using RRRRRR-LNP, RRERRR-LNP, and RRRYRR-LNP, respectively.

[0119] Figure 29 shows the calculated binding free energy of 6R and the two mutants with Vtn in Example 6.1 (a) and the analysis of the adsorbed Vtn content in the experiment (b).

[0120] Figure 30 shows the energy release rates of 6R and the two mutants with Vtn calculated in Example 6.1.

[0121] Figure 31 is a stacked bar chart showing the distribution and relative expression levels of luciferase in organs of each polypeptide-modified liposome in Example 6.2.

[0122] Figure 32 shows the results of the binding free energy of each polypeptide with Vtn calculated in Example 6.2.

[0123] Figure 33 shows the energy release rates of each polypeptide and Vtn calculated in Example 6.2.

[0124] Figure 34 is a stacked bar chart showing the relative expression levels of luciferase in organs for each polypeptide-modified liposome in Example 6.3.

[0125] Figure 35 shows the results of the binding free energy of each polypeptide with Vtn calculated in Example 6.3. Detailed Implementation

[0126] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0127] It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the invention. Furthermore, with respect to numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Any stated value or intermediate value within a stated range, as well as each smaller range between any other stated value or intermediate value within said range, is also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0128] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.

[0129] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be readily apparent to those skilled in the art. This specification and embodiments are merely exemplary.

[0130] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.

[0131] Terminology Explanation:

[0132] Fmoc-Arg(Pbf)-OH refers to Fmoc-protective arginine, CAS number 154445-77-9.

[0133] HOBT refers to 1-hydroxybenzotriazole, CAS number 2592-95-2.

[0134] DIC stands for N,N'-diisopropylcarbodiimide, CAS number 693-13-0.

[0135] Fmoc-Cys(Trt)-OH refers to N-fluorenylmethoxycarbonyl-S-triphenylmethyl-L-cysteine, CAS number 103213-32-7

[0136] Fmoc-Asp(OtBu)-OH refers to fluorenemethyloxycarbonyl-aspartic acid-4-tert-butyl ester, CAS number 71989-14-5.

[0137] DSPC refers to distearylphosphatidylcholine, CAS number 816-94-4.

[0138] DOPC refers to 1,2-dioleoyl-SN-glycerol-3-phosphocholine, CAS number 4235-95-4

[0139] DOPE refers to 1,2-dioleoylpropanetriyl-3-phosphatidylethanolamine, CAS No. 4004-05-1.

[0140] HSPC refers to hydrogenated soybean phosphatidylcholine, CAS number 92128-87-5.

[0141] ESM refers to lecithin, CAS number 860061C.

[0142] Mal-PEG2k-DSPE refers to maleimide-polyethylene glycol-phospholipid, purchased from Guangzhou Carbon Co., Ltd.

[0143] DSPE-PEG refers to phospholipid-polyethylene glycol, purchased from Guangzhou Carbon Co., Ltd.

[0144] The excipients used in the preparation of liposomes, such as ionized lipids SM102, MC3, ALC0315 and LP01, were purchased from Xiamen Sinobond Biotechnology Co., Ltd.

[0145] The correspondence between the amino acid or amino acid residue names in the polypeptide of this application is as follows: Cys: cysteine, abbreviated as C; Lys: lysine, abbreviated as K; His: histidine, abbreviated as H; Arg: arginine, abbreviated as R; Asp: aspartic acid, abbreviated as D; Glu: glutamic acid, abbreviated as E; Thr: threonine, abbreviated as T.

[0146] In one aspect, this application provides a peptide-modified lipid material, which is obtained by coupling a peptide to a lipid material containing polyethylene glycol chains.

[0147] The polypeptide is Cys-(X)n, wherein X is any one or any two of Lys, His, Arg, Asp, Glu or Thr, and n is the total number of X and is an integer in the range of greater than 1 and less than 11.

[0148] The polypeptide is coupled to the polyethylene glycol chain via a thiol group on its cysteine ​​residue.

[0149] In one specific embodiment, X in the polypeptide described in this application is Lys, that is, the polypeptide is Cys-(Lys)n.

[0150] In some specific embodiments, when the polypeptide is Cys-(Lys)n, n = 2, 3, 4, 5, 6, 7, 8, or 10. In some preferred embodiments, n = 3, 4, 5, 6, 7, or 8. For example, the polypeptide is Cys-(Lys)3, Cys-(Lys)4, Cys-(Lys)5, Cys-(Lys)6, Cys-(Lys)7, or Cys-(Lys)8.

[0151] In one specific embodiment, when X in the polypeptide described in this application is Lys, Lys can be partially replaced with Arg. In this case, n is the total number of Lys and Arg. For example, in some specific embodiments, the polypeptide is Cys-(Lys)3(Arg)3, Cys-(Lys)4(Arg)2, or Cys-(Lys)5(Arg)1, etc.

[0152] In one specific embodiment, X in the polypeptide described in this application is His, that is, the polypeptide is Cys-(His)n.

[0153] In some specific embodiments, when the polypeptide is Cys-(His)n, n = 2, 3, 4, 5, 6, 7, 8, or 10. For example, the polypeptide is Cys-(His)2, Cys-(His)3, Cys-(His)4, Cys-(His)5, Cys-(His)6, Cys-(His)7, Cys-(His)8, or Cys-(His)10. In some preferred embodiments, n in Cys-(His)n = 3, 4, 5, 6, 7, or 8.

[0154] In one specific embodiment, X in the polypeptide described in this application is Arg, that is, the polypeptide is Cys-(Arg)n.

[0155] In some specific embodiments, when the polypeptide is Cys-(Arg)n, n = 3, 4, 5, 6, 7, or 8. For example, the polypeptide is Cys-(Arg)3, Cys-(Arg)4, Cys-(Arg)5, Cys-(Arg)6, Cys-(Arg)7, or Cys-(Arg)8.

[0156] In this application, the polypeptide may be represented by abbreviated letters.

[0157] For example, Cys-(His)6 can be represented as 6H or HHHHHH, Cys-(Lys)6 can be represented as 6K or KKKKKK, Cys-(Lys)8 can be represented as 8K or KKKKKKKK, and so on.

[0158] When X consists of two amino acids or R is partially replaced by K, the position of the abbreviation in the polypeptide can also indicate the position of each amino acid in X. For example, RRRRRK represents Cys-(Arg)5(Lys)1, with Lys located at the end of the peptide; DDEEDD represents Cys-(Asp)4(Glu)2, with the two Glus located in the middle of the peptide; DDDDTT represents Cys-(Asp)4(Thr)2, with the two Thr located at the end of the peptide.

[0159] In a specific embodiment, the lipid material containing polyethylene glycol chains is Mal-PEG2k-DSPE.

[0160] This application also provides the use of the above-mentioned peptide-modified lipid materials in the preparation of peptide-modified liposomes for targeted drug delivery.

[0161] In a specific implementation, the drug is a nucleic acid drug.

[0162] In a specific embodiment, the peptide-modified liposomes for targeted drug delivery target organs in vivo.

[0163] In a specific implementation, the internal organ is the placenta, bone marrow, adipose tissue, or testis.

[0164] This application also provides a peptide-modified liposome for targeted drug delivery, wherein the raw materials for preparing the peptide-modified liposome include the above-mentioned peptide-modified lipid material.

[0165] In a specific embodiment, the raw materials for preparing the polypeptide-modified liposomes also include ionized lipids, phospholipids, cholesterol, and phospholipid-polyethylene glycol.

[0166] In some specific embodiments, the phospholipid may be selected from distearylphosphatidylcholine, 1,2-dioleoyl-SN-glycerol-3-phosphocholine, 1,2-dioleoylpropanetriyl-3-phosphatidylethanolamine, hydrogenated soybean phosphatidylcholine, or lecithin.

[0167] In some specific embodiments, the ionized lipid may be selected from MC3, SM102, ALC0315 or LP01.

[0168] In a specific embodiment, the molar ratio of the ionized lipid, the phospholipid, the cholesterol, the polypeptide-modified lipid material, and the phospholipid-polyethylene glycol in the polypeptide-modified liposome is (40-60):(5-15):(30-45):(3-12):(0.5-1.5).

[0169] In one specific embodiment, the molar ratio of the ionized lipid, the phospholipid, the cholesterol, the polypeptide-modified lipid material, and the phospholipid-polyethylene glycol is 50:10:38.5:6:0.75.

[0170] In another specific embodiment, the molar ratio of the ionized lipid, the phospholipid, the cholesterol, the polypeptide-modified lipid material, and the phospholipid-polyethylene glycol is 50:10:38.5:3:0.75.

[0171] This application also provides the application of the above-mentioned peptide-modified lipid materials or peptide-modified liposomes in improving drug targeting.

[0172] This application also provides the application of the above-mentioned peptide-modified lipid materials or peptide-modified liposomes in the preparation of drugs targeting organs in vivo.

[0173] In a specific implementation, the internal organ is the placenta, bone marrow, adipose tissue, or testis.

[0174] This application also provides a method for improving drug targeting, which includes using the above-mentioned peptide-modified lipid material or peptide-modified liposome.

[0175] Another aspect of this application provides a lung-targeting polypeptide sequence, wherein the energy relationship between the polypeptide sequence and vilinkin (Vtn) satisfies the following condition:

[0176] and / or

[0177] The binding free energy (ΔGBIND) is less than -30 kcal / mol.

[0178] In this application, the energy release rate (G) is the cleavage energy at the interface between the polypeptide sequence and fibronectin; the binding free energy (ΔG) is... BIND The molecular mechanical energy (G) between the polypeptide sequence and glassin is... GAS ) and solvation energy (G SOLV ) and.

[0179] In this application, the vitronectin (Vtn), also known as S-protein or serum diffusion factor, is a monomeric glycoprotein composed of two single-chain glycoproteins (65kD and 75kD) and is present in plasma and extracellular matrix.

[0180] In a specific implementation, the energy release rate (G) can be obtained by simulating the dissociation / pull-out process between the polypeptide sequence and Vtn using a Steered Molecular Dynamics model, and further by quantifying the fracture resistance of the binding interface.

[0181] In a specific implementation, the energy release rate is the ratio of the mechanical work (W) of the polypeptide sequence and glassin in the molecular dynamics model to the nominal contact area (S).

[0182] In a specific implementation, the mechanical work (W) can be obtained as follows: a complex model of the polypeptide sequence and Vtn is constructed in a stretching molecular dynamics model, and the polypeptide sequence is stretched along the vector direction at a constant rate (1 nm / ns). The vector direction of the polypeptide is defined as the direction of the line connecting the terminal amino acid of the polypeptide away from the binding pocket to the α-carbon atom coordinate of the starting amino acid at the other end. The area under the internal force-stretching curve of the polypeptide being pulled out of the complex structure is calculated by integral calculation, which is the mechanical work (W).

[0183] In a specific embodiment of this application, when constructing a complex model of a polypeptide sequence and Vtn, the polypeptide sequence and Vtn are linked by a Cys amino acid.

[0184] In one specific embodiment, in the complex structure in which the polypeptide sequence is bound to gellin, the polypeptide is stretched at a constant rate of 1 nm / ns along the direction of the vector ending at Cys. The area under the force-stretch curve that pulls the polypeptide out of the complex structure is calculated by integral calculation, which is the mechanical work (W).

[0185] In specific implementations, composite models can be constructed using NAMD software and tools such as CHARMM36 force fields.

[0186] In a specific implementation, the nominal contact area (S) is obtained by the following formula: S = n × L × b,

[0187] Where n is the number of amino acids contained in the polypeptide sequence, L is the average length of each amino acid in the polypeptide sequence, and b is the average width of each amino acid in the polypeptide sequence.

[0188] In some specific implementations, n is a natural number. Preferably, n is selected from 3, 4, 5, 6, 7, 8, 9, 10, or 11.

[0189] In a specific implementation, the energy release rate is calculated using the formula G = W / nLb.

[0190] In this application, the binding free energy (ΔG) of the polypeptide to Vtn is... BIND The binding strength can be quantified based on MMPBSA (molecular mechanics / Poisson-Boltzmann surface area).

[0191] In a specific implementation, the free energy (ΔG) is combined with BIND ) by molecular mechanics terms energy (G GAS =G BOND +G ANGLE +G DIHED +G VDWAALS +G EEL ) and solvation energy (GSOLV =E PB +E SURF It consists of two parts, ultimately yielding ΔG. BIND =G GAS +G SOLV .

[0192] In a specific implementation, the first three terms in the molecular mechanics terms represent covalent interactions, including the bond stretching energy (G) between two atoms that form a covalent bond. BOND =ΣK b (b-b0) 2 (where b is the bond length, subscript 0 indicates the equilibrium value, and K is the corresponding force constant), and the angular bending energy (G) between the three atoms interacting at the bonding angle. ANGLE =ΣK θ (θ-θ0) 2 θ is the bond angle, the subscript 0 indicates the equilibrium value, and K is the corresponding force constant), representing the dihedral torsional energy (G) of the dihedral interaction. DIHED =ΣK χ (1-cos(nχ-δ)), where χ is the dihedral angle, n is the dihedral angle period, δ is the phase angle, and K is the corresponding force constant); the last two terms describe the van der Waals interaction (G) that describes the non-covalent interaction between atoms. VDWAALS =Σε[(R min / r ij ) 12 -(R min / r ij ) 6 ], where ε is the Lennard-Jones potential well depth, R min It is the distance at the minimum of the Lennard-Jones potential, r ij (the distance between atoms i and j) and electrostatic interaction (G) EEL =Σq i q j / ε1r ij q i q j (where ε is the atomic charge and ε1 is the effective dielectric constant).

[0193] In a specific implementation, the solvation energy can be divided into two parts: polar solvation energy (E calculated using the Poisson-Boltzmann method). PB ) and nonpolar solvation energy (proportional to the solvent accessible surface area SASA, E) SURF =γ·SASA+β).

[0194] In this application, the binding free energy (ΔG) of the polypeptide to Vtn is... BINDSimulations can be performed using the GROMACS 2020.6 package under the CHARMM 36 force field and TIP3P water model.

[0195] In this application, the energy release rate (G) and binding free energy (ΔG) are calculated. BIND The parameters of the molecular dynamics force field are empirical parameters, which are widely used and verified, and can all be given by appropriate molecular dynamics simulation software.

[0196] In some specific embodiments of this application, the lung-targeting polypeptide sequence is RRRRRR (Seq ID No. 1) or RRRYRR (Seq ID No. 2).

[0197] Another aspect of this application provides a peptide-modified lipid material with lung-targeting properties.

[0198] In a specific embodiment, the polypeptide-modified lipid material is obtained by coupling a polypeptide to a lipid material containing polyethylene glycol chains;

[0199] The polypeptide comprises the polypeptide sequence provided in this application.

[0200] In a specific embodiment, the polypeptide in the polypeptide-modified lipid material is Cys-X, where X is the lung-targeting polypeptide sequence provided in this application.

[0201] In some specific embodiments, the peptide in the peptide-modified lipid material is CRRRRRR (Seq ID No. 3) or CRRRYRR (Seq ID No. 4).

[0202] In specific implementations, the positions of abbreviated letters in a peptide can indicate the positions of the corresponding amino acids or residues. For example, CRRRYRR indicates that Tyr is located in the middle of the peptide and the two Args are located at the ends of the peptide; CDDDDTT indicates that the two Thres are located at the ends of the peptide.

[0203] In a specific embodiment, the polypeptide-modified lipid material is coupled to the polyethylene glycol chain via a cysteine ​​residue (Cys) at one end of the polypeptide.

[0204] In a specific embodiment, the lipid material containing polyethylene glycol chains is Mal-PEG. 2k -DSPE.

[0205] Another aspect of this application provides a peptide-modified liposome for targeted drug delivery.

[0206] In a specific embodiment, the raw materials for preparing the polypeptide-modified liposomes include the polypeptide-modified lipid material provided in this application.

[0207] In a specific embodiment, the raw materials for preparing the polypeptide-modified liposomes also include ionized lipids, phospholipids, cholesterol, and phospholipid-polyethylene glycol.

[0208] In some specific embodiments, the phospholipid may be selected from distearylphosphatidylcholine, 1,2-dioleoyl-SN-glycerol-3-phosphocholine, 1,2-dioleoylpropanetriyl-3-phosphatidylethanolamine, hydrogenated soybean phosphatidylcholine, or lecithin.

[0209] In some specific embodiments, the ionized lipid may be selected from MC3, SM102, ALC0315 or LP01.

[0210] In a specific embodiment, the molar ratio of the ionized lipid, the phospholipid, the cholesterol, the polypeptide-modified lipid material, and the phospholipid-polyethylene glycol in the polypeptide-modified liposome is (40-60):(5-15):(30-45):(3-12):(0.5-1.5).

[0211] In one specific embodiment, the molar ratio of the ionized lipid, the phospholipid, the cholesterol, the polypeptide-modified lipid material, and the phospholipid-polyethylene glycol is 50:10:38.5:6:0.75.

[0212] This application also provides the application of the above-mentioned peptide-modified lipid materials or peptide-modified liposomes in the preparation of lung-targeted drug delivery.

[0213] This application also provides the application of the above-mentioned peptide-modified lipid materials or peptide-modified liposomes in improving drug lung targeting.

[0214] This application also provides a method for improving drug lung targeting, which includes using the above-mentioned peptide-modified lipid material or peptide-modified liposomes.

[0215] Another aspect of this application provides a method for screening organ-targeting polypeptide sequences, comprising:

[0216] The energy relationship between the target polypeptide sequence and the target protein that mediates organ targeting is obtained, and the energy relationship is used to determine whether the target polypeptide sequence has organ targeting specificity.

[0217] Wherein, the energy relationship refers to the cleavage energy at the binding interface between the target polypeptide sequence and the target protein, expressed as energy release rate (G), and / or the molecular mechanical energy (G0) between the target polypeptide sequence and the target protein. GAS) and solvation energy (G SOLV The sum of ) to combine the free energy (ΔG) BIND )express.

[0218] In a specific implementation, the energy relationship between the target polypeptide sequence and the target protein mediating organ targeting is obtained, and the energy relationship is judged. If the following conditions are met, the target polypeptide sequence is considered to have the organ targeting property:

[0219] and / or

[0220] Combined free energy (ΔG) BIND < -30 kcal / mol.

[0221] In one specific embodiment, this application provides a method for screening peptide sequences with lung targeting, comprising:

[0222] Obtain the energy relationship between the target polypeptide sequence and the target protein. The target polypeptide sequence is considered to have lung targeting if the following conditions are met:

[0223] and / or

[0224] Combined free energy (ΔG) BIND <30 kcal / mol

[0225] Wherein, the target protein is vitrin (Vtn), the energy release rate (G) is the cleavage energy at the interface between the polypeptide sequence and the target protein, and the binding free energy (ΔG) is... BIND ) is the molecular mechanical energy (G) between the polypeptide sequence and the target protein. GAS ) and solvation energy (G SOLV ) and.

[0226] In a specific implementation, the energy release rate (G) is the ratio of the mechanical work (W) of the polypeptide sequence and the target protein in the molecular dynamics model to the nominal contact area (S).

[0227] In a specific implementation, the mechanical work (W) is obtained in the following manner:

[0228] In the complex structure in which the peptide binds to the target protein, the peptide is stretched along its vector direction at a constant rate of 1 nm / ns. The vector direction of the peptide is defined as the direction of the line connecting the terminal amino acid at the end far from the binding pocket and the starting amino acid at the other end. The area under the force-stretch curve within the displacement range of the peptide being pulled out of the complex structure is calculated by integral and is the mechanical work (W).

[0229] In a specific implementation, the nominal contact area (S) is obtained by the following formula: S = n × L × b,

[0230] Where n is the number of amino acids contained in the polypeptide sequence, L is the average length of each amino acid in the polypeptide sequence, and b is the average width of each amino acid in the polypeptide sequence.

[0231] In some specific implementations, n is a natural number. Preferably, n is selected from 3, 4, 5, 6, 7, 8, 9, 10, or 11.

[0232] In a specific implementation, the molecular mechanical energy (G) GAS It is derived from the following formula:

[0233] G GAS =G BOND +G ANGLE +G DIHED +G VDWAALS +G EEL ,in,

[0234] G BOND =ΣK b (b-b0) 2 G ANGLE =ΣK θ (θ-θ0) 2 G DIHED =ΣK χ (1-cos(nχ-δ)), G VDWAALS =Σε[(R min / r ij ) 12 -(R min / r ij ) 6 ], G EEL =Σq i q j / ε1r ij .

[0235] In a specific implementation, b is the covalent bond length, b0 is the equilibrium value, θ is the covalent bond angle, θ0 is the equilibrium value, χ is the dihedral angle, n is the dihedral angle period, δ is the phase angle, and K... b K θ K χ R is the force constant, ε is the depth of the Lennard-Jones potential well, and R is the force constant. min r is the distance at the minimum of the Lennard-Jones potential. ij q is the distance between atoms i and j. i q j ε is the atomic charge, and ε1 is the effective dielectric constant.

[0236] In a specific implementation, the solvation energy (G) SOLV ) is the polar solvation energy (E PB ) and nonpolar solvation energy (E SURF The sum of the polar solvation energies (E) PB The nonpolar solvation energy (E) was calculated using the Poisson-Boltzmann method. SURF )=γ·SASA+β.

[0237] In this application, the energy release rate (G) and binding free energy (ΔG) are calculated. BIND The parameters of the molecular dynamics force field are empirical parameters that are widely used and verified, and can be given by appropriate molecular dynamics simulation software, including but not limited to NAMD and GROMACS.

[0238] The EGFP mRNA and Luciferase mRNA used in the following examples were purchased from Trilink.

[0239] Example

[0240] Example 1: Synthesis and Characterization of Polypeptides

[0241] 1.1 Synthesis of polypeptides

[0242] In this example, three polypeptides, 6H (SEQ ID No. 20), 6K (SEQ ID No. 21), and 8K (SEQ ID No. 22), were designed. Their chemical structures are shown in Figure 1, AC, respectively. The specific synthesis methods are as follows:

[0243] (1) Synthesis and preparation of 6H:

[0244] a) Select 1 gram of Wang resin with a loading of 1 mmol / g, add 1.3 g of the first amino acid Fmoc-His(Trt)-OH, 1 g of HOBT, and 1 mL of DIC, purge with nitrogen for protection, and react for 6 hours.

[0245] b) Draw up the reaction liquid, test with ninhydrin. After the resin is colorless, wash it four times alternately with DMF and DCM, add 20 ml of piperidine solution, react for 15 minutes, and remove Fmoc protection.

[0246] c) Wash four times alternately with DMF and DCM. Detect with ninhydrin. If the resin turns brown, it indicates that Fmoc has been removed and the next amino acid reaction can proceed.

[0247] d) Add 1.3 g of the second amino acid Fmoc-His(Trt)-OH, 0.5 g of HOBT, and 0.5 mL of DIC. React for 2 hours, monitoring with ninhydrin. If the resin is colorless, remove Fmoc protection with piperidine solution before proceeding to the next step.

[0248] e) Add raw materials sequentially according to the target polypeptide sequence until the last amino acid Fmoc-Cys(Trt)-OH of the polypeptide sequence is synthesized and Fmoc protection is removed.

[0249] f) The resin was washed clean, dried, and pyrolyzed with TFA; it was then settled by ice-cold ether and centrifuged to obtain 6H solid.

[0250] (2) Synthesis and preparation of 6K:

[0251] a) Select 1 gram of Wang resin with a loading of 1 mmol / g, add 1.3 g of the first amino acid Fmoc-Lys(Boc)-OH, 1 g of HOBT, and 1 mL of DIC, purge with nitrogen for protection, and react for 6 hours.

[0252] b) Draw up the reaction liquid, test with ninhydrin. After the resin is colorless, wash it four times alternately with DMF and DCM, add 20 ml of piperidine solution, react for 15 minutes, and remove Fmoc protection.

[0253] c) Wash four times alternately with DMF and DCM. Detect with ninhydrin. If the resin turns brown, it indicates that Fmoc has been removed and the next amino acid reaction can proceed.

[0254] d) Add 1.3 g of the second amino acid Fmoc-Lys(Boc)-OH, 0.5 g of HOBT, and 0.5 mL of DIC. React for 2 hours, monitoring with ninhydrin. If the resin is colorless, remove Fmoc protection with piperidine solution and proceed to the next step.

[0255] e) Add raw materials sequentially according to the target polypeptide sequence until the last amino acid Fmoc-Cys(Trt)-OH of the polypeptide sequence is synthesized and Fmoc protection is removed.

[0256] f) The resin was washed clean, dried, and pyrolyzed with TFA; it was then settled in ice-cold ether, centrifuged, and 6K solid was obtained.

[0257] (3) Synthesis and preparation of 8K:

[0258] a) Select 1 gram of Wang resin with a loading of 1 mmol / g, add 1.3 g of the first amino acid Fmoc-Lys(Boc)-OH, 1 g of HOBT, and 1 mL of DIC, purge with nitrogen for protection, and react for 6 hours.

[0259] b) Draw up the reaction liquid, test with ninhydrin. After the resin is colorless, wash it four times alternately with DMF and DCM, add 20 ml of piperidine solution, react for 15 minutes, and remove Fmoc protection.

[0260] c) Wash four times alternately with DMF and DCM. Detect with ninhydrin. If the resin turns brown, it indicates that Fmoc has been removed and the next amino acid reaction can proceed.

[0261] d) Add 1.3 g of the second amino acid Fmoc-Lys(Boc)-OH, 0.5 g of HOBT, and 0.5 mL of DIC. React for 2 hours, monitoring with ninhydrin. If the resin is colorless, remove Fmoc protection with piperidine solution and proceed to the next step.

[0262] e) Add raw materials sequentially according to the target polypeptide sequence until the last amino acid Fmoc-Cys(Trt)-OH of the polypeptide sequence is synthesized and Fmoc protection is removed.

[0263] f) The resin was washed clean, dried, and pyrolyzed with TFA; it was then settled by ice-cold ether, centrifuged, and 8K solid was obtained.

[0264] Example 2: Preparation of peptide-modified liposomes (LNPs)

[0265] 2.1 Preparation of ESM-6H-LNP

[0266] Take 1 mmol of the 6H peptide synthesized in step 1.1 and 1 mmol of Mal-PEG. 2k -DSPE was added to the reaction flask, and then the following operations were performed: 10 mL of ultra-dry solvent (tetrahydrofuran) was added under argon protection to dissolve the DSPE, followed by 10 μL of freshly evaporated acid-binding agent. The flask was sealed and stirred at room temperature for 24 hours. The reaction solution was then placed in a dialysis bag and dialyzed with ultrapure water for 3 days. The solution was then lyophilized to obtain the final product DSPE-PEG. 2k -6H (peptide-modified lipid material), the chemical structure of the product was characterized using 1H NMR spectroscopy to verify whether the peptide was successfully coupled to PEG. 2k -DSPE, and the results are shown in Figure 2a. Five lipid components (ionized lipid MC3, cholesterol, lecithin ESM, DSPE-PEG) were analyzed. 2kEGFP mRNA was dissolved in ethanol (alcohol phase) at a molar ratio of 50:38.5:35:6:0.75, and EGFP mRNA was dissolved in citrate buffer (aqueous phase). The ionized lipids and mRNA were prepared with an N / P ratio of 5.67. The volume ratio of alcohol phase to aqueous phase was 1:3. The alcohol phase and aqueous phase were flowed at a flow rate ratio of 1:3 (0.3 mL / min for alcohol phase and 0.9 mL / min for aqueous phase) through the microfluidic channel shown in Figure 3. The peptide-modified liposomes were collected. Finally, the collected liquid was dialyzed overnight with 1×PBS to obtain ESM-6H-LNP encapsulated with EGFP mRNA.

[0267] 2.2 Preparation of 6K-3-LNP

[0268] Take 1 mmol of the 6K peptide synthesized in step 1.1 and 1 mmol of Mal-PEG. 2k -DSPE was added to the reaction flask, and then the following operations were performed: 10 mL of ultra-dry solvent (tetrahydrofuran) was added under argon protection to dissolve the DSPE, followed by 10 μL of freshly evaporated acid-binding agent. The flask was sealed and stirred at room temperature for 24 hours. The reaction solution was then placed in a dialysis bag and dialyzed with ultrapure water for 3 days. The solution was then lyophilized to obtain the final product DSPE-PEG. 2k -6K (peptide-modified lipid material), the chemical structure of the product was characterized using 1H NMR spectroscopy to verify whether the peptide was successfully coupled to PEG. 2k -DSPE, and the results are shown in Figure 2b. Five lipid components (ionized lipid MC3, cholesterol, phospholipid DSPC, DSPE-PEG) were analyzed. 2k EGFP mRNA was dissolved in ethanol (alcohol phase) at a molar ratio of 50:38.5:10:3:0.75, and EGFP mRNA was dissolved in citrate buffer (aqueous phase). The ionized lipids and mRNA were prepared at an N / P ratio of 5.67. The volume ratio of alcohol phase to aqueous phase was 1:3. The alcohol phase and aqueous phase were flowed at a flow rate ratio of 1:3 (0.3 mL / min for alcohol phase and 0.9 mL / min for aqueous phase) through the microfluidic channel shown in Figure 3. The peptide-modified liposomes were collected. Finally, the collected liquid was dialyzed overnight with 1×PBS to obtain 6K-3-LNP encapsulated with EGFP mRNA.

[0269] 2.3 Preparation of 8K-LNP

[0270] Take 1 mmol of the 8K peptide synthesized in step 1.1 and 1 mmol of Mal-PEG. 2k-DSPE was added to the reaction flask, and then the following operations were performed: 10 mL of ultra-dry solvent (tetrahydrofuran) was added under argon protection to dissolve the DSPE, followed by 10 μL of freshly evaporated acid-binding agent. The flask was sealed and stirred at room temperature for 24 hours. The reaction solution was then placed in a dialysis bag and dialyzed with ultrapure water for 3 days. The solution was then lyophilized to obtain the final product DSPE-PEG. 2k -8K (peptide-modified lipid material), the chemical structure of the product was characterized using 1H NMR spectroscopy to verify whether the peptide was successfully coupled to PEG. 2k -DSPE, and the results are shown in Figure 2c. Five lipid components (ionized lipid MC3, cholesterol, phospholipid DSPC, DSPE-PEG) were analyzed. 2k 8K-8K and DSPE-PEG were dissolved in ethanol (alcohol phase) at a molar ratio of 50:38.5:10:6:0.75, and EGFP mRNA was dissolved in citrate buffer (aqueous phase). The ionized lipids and mRNA were prepared at an N / P ratio of 5.67. The volume ratio of alcohol phase to aqueous phase was 1:3. The alcohol phase and aqueous phase were flowed at a flow rate ratio of 1:3 (0.3 mL / min for alcohol phase and 0.9 mL / min for aqueous phase) through the microfluidic channel shown in Figure 3. The peptide-modified liposomes were collected. Finally, the collected liquid was dialyzed overnight with 1×PBS to obtain 8K-LNP encapsulated with EGFP mRNA.

[0271] 2.4 Preparation of 6K-LNP

[0272] Take 1 mmol of the 6K peptide synthesized in step 1.1 and 1 mmol of Mal-PEG. 2k -DSPE was added to the reaction flask, and then the following operations were performed: 10 mL of ultra-dry solvent (tetrahydrofuran) was added under argon protection to dissolve the DSPE, followed by 10 μL of freshly evaporated acid-binding agent. The flask was sealed and stirred at room temperature for 24 hours. The reaction solution was then placed in a dialysis bag and dialyzed with ultrapure water for 3 days. The solution was then lyophilized to obtain the final product DSPE-PEG. 2k -6K (peptide-modified lipid material), the chemical structure of the product was characterized using 1H NMR spectroscopy to verify whether the peptide was successfully coupled to PEG. 2k -DSPE, and the results are shown in Figure 2b. Five lipid components (ionized lipid MC3, cholesterol, phospholipid DSPC, DSPE-PEG) were analyzed. 2kEGFP mRNA was dissolved in ethanol (alcohol phase) at a molar ratio of 50:38.5:10:6:0.75, and EGFP mRNA was dissolved in citrate buffer (aqueous phase). The ionized lipids and mRNA were prepared at an N / P ratio of 5.67. The volume ratio of alcohol phase to aqueous phase was 1:3. The alcohol phase and aqueous phase were flowed at a flow rate ratio of 1:3 (0.3 mL / min for alcohol phase and 0.9 mL / min for aqueous phase) through the microfluidic channel shown in Figure 3. The peptide-modified liposomes were collected. Finally, the collected liquid was dialyzed overnight with 1×PBS to obtain 6K-LNP encapsulated with EGFP mRNA.

[0273] Example 3: Study on selective delivery of peptide-modified liposomes to organs or tissues

[0274] Targeting performance studies were conducted on organs or tissues such as adipose tissue and testes. Four-component LNPs (TLNPs or ESM-TLNPs) without peptide modification were prepared using the same method for control experiments.

[0275] 3.1 In vitro organ fluorescence imaging

[0276] To quantify the luminescence intensity in ex vivo organ chemiluminescence images, the average luminescence brightness of each organ was measured using in vivo imaging software. The organ selectivity of LNPs was characterized by the average luminescence radiation ratio across different organs. For ex vivo organ fluorescence (EGFP, tdTomato) imaging and analysis, absolute fluorescence was quantified using Living Imaging software. Since tissues have a significant autofluorescence background, changes in fluorescence brightness (i.e., the average fluorescence difference between the LNP-treated group and the PBS-treated group) reflect the LNP delivery effect. The percentage of this brightness change in different organs was calculated to compare and illustrate the organ-selective delivery performance. The fluorescence level of EGFP in tissue sections was determined using mean fluorescence intensity (MFI). Data were analyzed using GraphPad Prism 9.5 software, and mean ± standard deviation (SD) was plotted. One-way ANOVA and Tukey's post-hoc test, or unpaired Student's t-test, were used to assess statistical significance, as shown in the figure above. (*: p < 0.05; **: p < 0.001; ****: p < 0.0001). GraphPad Prism 9.5 software was used to annotate statistical differences.

[0277] 3.1-A The 6K-3-LNP and TLNP encapsulated with EGFP mRNA obtained in step 2.2 were injected intravenously into pregnant mice (E16.5) at a dose of 0.3 mg / kg. Six hours after injection, in vitro organ EGFP fluorescence imaging was performed on isolated mouse placentas, livers, lungs, spleens, hearts, and kidneys. The results are shown in Figures 4-6. Figure 4 shows in vivo imaging images using 6K-3-LNP, TLNP, and PBS, respectively; Figure 5 shows the statistical results of quantitative analysis of the absolute fluorescence intensity of EGFP in the placenta, liver, lungs, and spleen (n = 3 animals for each case); Figure 6 shows the percentage change in EGFP fluorescence intensity in each organ of the placenta, liver, lungs, and spleen.

[0278] 3.1-B The ESM-6H-LNP and ESM-TLNP, which encapsulate EGFP mRNA obtained in step 2.1, were injected into mice via the tail vein at a dose of 0.3 mg / kg. Six hours after injection, in vitro organ EGFP fluorescence imaging was performed on isolated mouse organs, including bone marrow, liver, lung, spleen, heart, and kidney. The results are shown in Figures 7-9. Figure 7 shows in vivo imaging images using ESM-6H-LNP, ESM-TLNP, and PBS, respectively; Figure 8 shows the statistical results of quantitative analysis of the absolute fluorescence intensity of EGFP in bone marrow, liver, lung, and spleen (n = 3 animals for each case); Figure 9 shows the percentage change in EGFP fluorescence intensity in each organ, including bone marrow, liver, lung, and spleen.

[0279] 3.1-C The 8K-LNP and TLNP encapsulated with EGFP mRNA obtained in step 2.3 were administered intraperitoneally to mice at a dose of 0.4 mg / kg. Six hours after injection, in vitro organ EGFP fluorescence imaging was performed on isolated mouse adipose tissue, liver, lung, spleen, heart, and kidney. The results are shown in Figures 10-12. Figure 10 shows in vivo imaging images using 8K-LNP, TLNP, and PBS, respectively; Figure 11 shows the statistical results of quantitative analysis of the absolute fluorescence intensity of EGFP in adipose tissue, liver, lung, and spleen (n = 3 animals for each case); Figure 12 shows the percentage change in EGFP fluorescence intensity in each organ of adipose tissue, liver, lung, and spleen.

[0280] 3.1-D The 6K-LNP and TLNP encapsulated with EGFP mRNA obtained in step 2.4 were intraperitoneally injected into mice at a dose of 0.4 mg / kg. Six hours after injection, in vitro organ EGFP fluorescence imaging was performed on isolated mouse organs, including the testes, liver, lungs, spleen, heart, and kidneys. The results are shown in Figures 13-15. Figure 13 shows in vivo imaging images using 6K-LNP, TLNP, and PBS, respectively; Figure 14 shows the statistical results of quantitative analysis of the absolute fluorescence intensity of EGFP in the testes, liver, lungs, and spleen (n = 3 animals for each case); Figure 15 shows the percentage change in EGFP fluorescence intensity in each organ of the testes, liver, lungs, and spleen.

[0281] The above experimental results indicate that peptide-modified liposomes can deliver mRNA in vivo to the placenta, bone marrow, adipose tissue, and testes.

[0282] 3.2 Assessment of the ability of peptide-modified organ-targeting liposomes to deliver functional cells

[0283] The delivery of the peptide-modified LNPs to functional cells in target organs was evaluated. EGFP mRNA encapsulated within the LNPs was intravenously injected into mice at a dose of 0.4 mg / kg mRNA. Six hours post-injection, placenta (6K-3-LNP), bone marrow (ESM-6H-LNP), adipose tissue (8K-LNP), and testes (6K-LNP) were isolated and analyzed by flow cytometry.

[0284] First, the organ was isolated into single cells. Then, the resulting cell suspension was incubated with the corresponding antibody at 4°C in the dark for 20 minutes, as follows:

[0285] For flow cytometry analysis of adipose tissue, organs were isolated, washed with cold PBS, and then cut into small pieces according to the Miltenyi kit protocol. The pieces were resuspended in dissociation buffer. After incubation at 37°C for 15 min, the samples were filtered through a 70 μm filter, centrifuged at 400 g for 10 min, resuspended in 2.5 ml of erythrocyte lysis buffer, and finally washed with 1 part PBS (containing 5% FBS) to harvest cells. For placenta and testis, isolated tissues were cut into small pieces, resuspended in dissociation buffer (DMEM + 15% FBS + 2 mg ml-1 type IV collagenase + 7 mg ml-1 DNase) for 20 min, filtered through a 70 μm pore, centrifuged at 400 g for 10 min, resuspended in 1 ml of erythrocyte lysis buffer, and finally washed with 1 part PBS (containing 5% FBS) to collect cells. For bone marrow, femur and tibia were collected, centrifuged at 1000g for 5 min, cells were collected, filtered through a 100μm filter, centrifuged at 400g for 5 min, resuspended in 2 ml of red blood cell lysis buffer, and finally washed with 1x PBS (containing 5% FBS) for flow cytometry analysis.

[0286] Cell types within the EGFP+ cell populations of various target organs were analyzed: CK7+ trophoblasts in the placenta; Lin- / Sca1+ / CD117+ / CD34- / CD135- long-term hematopoietic stem cells (LT-HSCs) and Lin- / Sca1+ / CD117+ / CD34- / CD135- / CD150+ multilineage recombinant LT-HSCs in the bone marrow; CD140a+ / CD34+ / Sca1+ adipocyte progenitor cells in the adipose tissue; and Thy1+ spermatogonia and Thy1+ / ITGA6+ spermatogonial stem cells in the testes. EGFP signals were analyzed using fluorescence activated cell sorting (FACS) full-spectrum flow cytometry (SONY ID7000) for quantitative analysis of cells. FlowJo software was used for EGFP signal analysis and visualization.

[0287] The gating strategies for flow cytometry are shown in Figures 16-19. Figure 20 shows the percentage of EGFP+ cells in functional cells isolated from the target organ. Specifically, Figure 20a shows the percentage of EGFP+ cells in trophoblast cells (CK7+) isolated from the placenta after EGFP mRNA delivery to LNPs via placental targeting. Figure 20b shows the percentage of EGFP+ cells in long-term hematopoietic stem cells (LT-HSCs) (Lin / Sca1+ / CD117+ / CD34- / CD135-) and multi-lineage recombinant CD150+ LT-HSCs (Lin / Sca1+ / CD117+ / CD34- / CD135- / CD150+) from bone marrow. Figure 20c shows the percentage of EGFP+ cells in adipocyte progenitor cells (CD140a+ / Sca1+ / CD34+) isolated from adipose tissue after EGFP mRNA delivery to selective LNPs in adipose tissue. Figure 20d shows the percentage of EGFP+ cells in spermatogonia (Thy1+) and spermatogonial stem cells (Thy1+ / Itga6+) isolated from the testes after EGFP mRNA delivery via testicular selective LNPs. PBS was used as a control. n = 3 animals per case. P-values ​​were calculated using an unpaired Student's t-test, with ****P ≤ 0.001 and ****P ≥ 0.0001. All data are plotted as mean ± standard deviation.

[0288] The above results further verify that peptide-modified LNPs not only have the ability to target organs, but can also deliver mRNA nucleic acid drugs into the parenchymal cells of target organs, demonstrating broad application potential in the field of disease treatment.

[0289] Example 4: Calculation of Energy Release Rate (G value)

[0290] Taking peptide sequences 4R / 5R / 6R / 7R / 8R as an example, the dissociation / decoupling process of the polypeptide sequence polyR with Vtn was simulated using Steered Molecular Dynamics (SMD). The calculation results of this process were used to further quantify the fracture resistance of the binding interface. All SMD simulations were performed using the NAMD 2.14 package under the CHARMM 36 force field and TIP3P water model. Unless otherwise specified, the temperature used in the simulation was 300K and the pressure was 1 atm. In the detailed simulation parameter settings, 0.8 nm was used as the switching distance, 1 nm as the cutoff distance, and 1.2 nm as the maximum distance for the neighbor list calculation. 2 fs was set as the time step, which was changed to 1 fs in some simulations during the relaxation step to stabilize the simulation. Based on the PDB library code: 7RJ9, a full-atom vitrinin (Vtn) was prepared by MODELLER homology modeling. The structure was relaxed by the following steps: (1) Freeze each atom except for the atoms guessed by MODELLER and relax the structure for 1 ns; (2) Freeze the entire structure and relax it for 500 ps in an electron-neutralized periodic water box with an NVT ensemble water thickness of 0.7 nm (using a Na+ and Cl- ion neutralization system); (3) Perform simulation in the same way as step (2), except change the ensemble type to NPT; (4) Unfreeze all atoms and perform molecular system relaxation for 10 ns. The binding sites of the polyR peptide with the initial Vtn structure were predicted using the PepNN program, requiring a binding probability >0.7. Then, the polyR was manually fitted to the binding sites in the pocket rich in β-sheet structure to create as many binding sites as possible (water molecules and neutralizing ions were removed in this step). The binding site was defined as the contact distance between a non-hydrogen atom in the protein Vtn and any non-hydrogen atom in the polypeptide polyR. The residue positions. Then, the Vtn-polyR complex structure was relaxed: (1) the Vtn protein was frozen and the complex structure was relaxed for 500 ps; (2) the complex structure was frozen and relaxed for 500 ps in an NVT ensemble in a 1.2 nm water-thickness neutralized periodic water box; (3) the same simulation as step (2) was performed, except that the ensemble type was changed to NPT; (4) all atoms were thawed and the molecular system was relaxed for 60 ns. In all models, polyR and DSPE-PEG were linked by cysteine ​​(Cys). The structure obtained by the above molecular modeling was used as the initial structure for SMD simulation. In the SMD simulation, the α-carbon of the 66th residue of Vtn was fixed, while the α-carbon of the cysteine ​​Cys was pulled along the polyR backbone direction, i.e., the direction of the polypeptide ending at CYS. The bias potential of the SMD simulation was: V = 1 / 2k(r→ (t)-r → (0)-vte → ) 2 Where k is stiffness (or force constant), r → (t) represents the coordinates of the atom at time t due to the bias potential, v is the traction velocity, and e is the traction velocity. → It is the traction direction. In this simulation, k is set to... v was set to 1 nm / ns. To obtain the energy release rate in the SMD stretching simulation, the area under the force-stretch curve within the 0-4 nm stretching range of the peptide pulling out of the complex structure (as shown in Figure 21) was used as the input mechanical work (W), which was converted into the strain-free energy of the Vtn protein. The nominal contact area between polyR and Vtn was determined by the total number of residues (n) of the polyR peptide and the average length of the amino acid residues. and the average width of amino acid residues The product of these factors is used to estimate the energy release rate G. The formula for calculating the energy release rate G is G = W / nLb.

[0291] The calculated G-values ​​for each sequence are shown in Figure 22. The G-value of the 6R sequence is significantly higher than that of other variants such as 4R-8R, indicating that it has the best fracture resistance.

[0292] Criterion threshold: when At that time, the sequence has lung-targeting properties.

[0293] Example 5: Combining free energy (ΔG) BIND ) calculation

[0294] This application further proposes a method for estimating the binding strength of a peptide and Vtn based on their steady-state binding configuration, namely, a method based on binding free energy. The binding free energy between the peptide and Vtn is calculated using MMPBSA (molecular mechanics / Poisson-Boltzmann surface area) to quantify the binding strength.

[0295] Figure 23 is a schematic diagram of the lung-targeting peptide design based on the mechanoaffinity between peptide and Vtn. Figure 24 shows the conformation of peptide-Vtn complexes for different peptide sequences (including RRRRRR (Seq ID No. 1), RRERRR (Seq ID No. 5), and RRRYRR (Seq ID No. 2)) generated by AlphaFold3 (a Cys terminus is added to one end of the peptide sequence to couple with Vtn). All MD simulations here were performed using the GROMACS2020.6 package under the CHARMM 36 force field and TIP3P water model. Unless otherwise specified, the temperature used in the simulation was 300K and the pressure was 1 atm. Detailed simulation parameter settings used 0.8 nm as the switching distance, 1 nm as the cutoff distance, and 1.2 nm as the maximum distance for neighbor list calculation, with a time step of 2 fs. All force field parameters were provided by the GROMACS software, and calculations were performed using the gmx_MMPBSA tool. Based on the protein sequence of PDB library code 7RJ9 and the specified polypeptide sequence CRRRRRR, a Vtn-CRRRRRR complex structure with high reliability was generated and screened in the AlphaFold3 online service website. The structure was balanced through the following steps: (1) minimizing the energy of the system using the steepest descent method; (2) heating the system to the target temperature for 100 ps in an NVT ensemble neutralized periodic water box (using Na+ and Cl- ion neutralization system); (3) pressurizing the system to the target pressure for 100 ps in an NPT ensemble neutralized periodic water box; (4) running a 10 ns equilibrium simulation in the NPT ensemble to relax the system. Subsequently, a protein language model called Structural-Evolution was used. The balanced Vtn-CRRRRRR complex structure was input, and the specified polypeptide chain CRRRRRR was mutated to obtain CRRERRR and CRRRYRR sequences. The above AlphaFold3 complex structure generation and MD equilibrium simulation process was repeated to obtain the balanced complex structure. The binding free energy ΔG between the peptide molecule and Vtn was assessed using the MMPBSA (molecular mechanics / Poisson-Boltzmann surface area) method. BIND Divided into molecular mechanics terms (G GAS =G BOND +G ANGLE +G DIHED +G VDWAALS +G EEL ) and solvation energy (G SOLV =E PB +E SURF The two parts ultimately yield ΔG. BIND =G GAS +G SOLVThe first three terms in the molecular mechanics terms represent covalent interactions, including the bond stretching energy (G) between two covalently bonded atoms. BOND =ΣK b (b-b0) 2 (where b is the bond length, subscript 0 indicates the equilibrium value, and K is the corresponding force constant), and the angular bending energy (G) between the three atoms interacting at the bonding angle. ANGLE =ΣK θ (θ-θ0) 2 θ is the bond angle, the subscript 0 indicates the equilibrium value, and K is the corresponding force constant), representing the dihedral torsional energy (G) of the dihedral interaction. DIHED =ΣK χ (1-cos(nχ-δ)), where χ is the dihedral angle, n is the dihedral angle period, δ is the phase angle, and K is the corresponding force constant); the last two terms describe the van der Waals interaction (G) that describes the non-covalent interaction between atoms. VDWAALS =Σε[(R min / r ij ) 12 -(R min / r ij ) 6 ], where ε is the Lennard-Jones potential well depth, R min It is the distance at the minimum of the Lennard-Jones potential, r ij (the distance between atoms i and j) and electrostatic interaction (G) EEL =Σq i q j / ε1r ij q i q j ε is the atomic charge, and ε1 is the effective dielectric constant. The solvation energy can be specifically divided into two parts: polar solvation energy (E calculated using the Poisson-Boltzmann method). PB ) and nonpolar solvation energy (proportional to the solvent accessible surface area SASA, E) SURF =γ·SASA+β). All the above results can be obtained by calculating using the gmx_MMPBSA tool. The specific steps are as follows: (1) Run a 100ns equilibrium simulation of the complex structure in the NPT ensemble, sample once every 100ps and output; (2) Use the gmx_MMPBSA tool to input the topology file and trajectory file of the equilibrium process, specify the calculation parameters including the Poisson Boltzmann parameter igb=5 and the salt concentration saltcon=0.15M, run the calculation program and output the results; (3) Average the binding free energy distribution of the equilibrium simulation process to obtain the binding free energy of each complex structure.

[0296] Criterion threshold: when ΔG BINDAt <-30 kcal / mol, this sequence exhibits lung targeting.

[0297] Example 6: Verification of peptide targeting

[0298] Peptide-modified liposomes were prepared for organ targeting experiments to verify the peptide targeting based on the G value and binding energy with Vtn.

[0299] 6.1 Prepare liposomes modified with peptides of 6R (RRRRRR) and its two mutants (RRERRR, RRRYRR) for organ targeting experiments and result verification (the peptides prepared in the examples all contain Cys residues, and C is omitted when abbreviated).

[0300] 6.1.1 Synthesis and preparation of 6R (Seq ID No. 3), RRERRR (Seq ID No. 6), and RRRYRR (Seq ID No. 4) peptides

[0301] Synthesis and preparation of 6R:

[0302] a) Select 1 g of Wang resin, with a loading of 1 mmol / g, add 1.3 g of the first amino acid Fmoc-Arg(Pbf)-OH, 1 g of HOBT, and 1 mL of DIC. Under nitrogen protection, react for 6 hours.

[0303] b) Draw up the reaction liquid, test with ninhydrin. After the resin is colorless, wash it four times alternately with DMF and DCM, add 20 ml of piperidine solution, react for 15 minutes, and remove Fmoc protection.

[0304] c) Wash four times alternately with DMF and DCM. Detect with ninhydrin. If the resin turns brown, it indicates that Fmoc has been removed and the next amino acid reaction can proceed.

[0305] d) Add 1.3 g of the second amino acid Fmoc-Arg(Pbf)-OH, 0.5 g of HOBT, and 0.5 mL of DIC. React for two hours, monitoring with ninhydrin. If the resin is colorless, remove Fmoc protection with piperidine solution before proceeding to the next step.

[0306] e) Add raw materials sequentially according to the target polypeptide sequence until the last amino acid Fmoc-Cys(Trt)-OH of the polypeptide sequence is synthesized and Fmoc protection is removed.

[0307] f) The resin was washed clean, dried, and pyrolyzed with TFA; it was then settled in ice-cold ether, centrifuged, and 6R solid was obtained.

[0308] Synthesis and preparation of RRERRR:

[0309] a) Select 1 g of Wang resin, with a loading of 1 mmol / g, add 1.3 g of the first amino acid Fmoc-Arg(Pbf)-OH, 1 g of HOBT, and 1 mL of DIC. Under nitrogen protection, react for 6 hours.

[0310] b) Draw up the reaction liquid, test with ninhydrin. After the resin is colorless, wash it four times alternately with DMF and DCM, add 20 ml of piperidine solution, react for 15 minutes, and remove Fmoc protection.

[0311] c) Wash four times alternately with DMF and DCM. Detect with ninhydrin. If the resin turns brown, it indicates that Fmoc has been removed and the next amino acid reaction can proceed.

[0312] d) Add 1.3 g of the second amino acid Fmoc-Arg(Pbf)-OH, 0.5 g of HOBT, and 0.5 mL of DIC. React for two hours, monitoring with ninhydrin. If the resin is colorless, remove Fmoc protection with piperidine solution before proceeding to the next step.

[0313] e) Add raw materials sequentially according to the target polypeptide sequence until the last amino acid Fmoc-Cys(Trt)-OH of the polypeptide sequence is synthesized and Fmoc protection is removed.

[0314] f) The resin was washed clean, dried, and pyrolyzed with TFA; it was then settled in ice-cold ether, centrifuged, and 6R solid was obtained.

[0315] Synthesis and preparation of RRRYRR:

[0316] a) Select 1 g of Wang resin, with a loading of 1 mmol / g, add 1.3 g of the first amino acid Fmoc-Arg(Pbf)-OH, 1 g of HOBT, and 1 mL of DIC. Under nitrogen protection, react for 6 hours.

[0317] b) Draw up the reaction liquid, test with ninhydrin. After the resin is colorless, wash it four times alternately with DMF and DCM, add 20 ml of piperidine solution, react for 15 minutes, and remove Fmoc protection.

[0318] c) Wash four times alternately with DMF and DCM. Detect with ninhydrin. If the resin turns brown, it indicates that Fmoc has been removed and the next amino acid reaction can proceed.

[0319] d) Add 1.3 g of the second amino acid Fmoc-Arg(Pbf)-OH, 0.5 g of HOBT, and 0.5 mL of DIC. React for two hours, monitoring with ninhydrin. If the resin is colorless, remove Fmoc protection with piperidine solution before proceeding to the next step.

[0320] e) Add raw materials sequentially according to the target polypeptide sequence until the last amino acid Fmoc-Cys(Trt)-OH of the polypeptide sequence is synthesized and Fmoc protection is removed.

[0321] f) The resin was washed clean, dried, and pyrolyzed with TFA; it was then settled in ice-cold ether, centrifuged, and 6R solid was obtained.

[0322] 6.1.2 Preparation of peptide-modified liposomes RRRRRR-LNP, RRERRR-LNP and RRRYRR-LNP

[0323] Take 1 mmol of each of the synthesized polypeptides and react them with 1 mmol of Mal-PEG. 2k -DSPE was added to the reaction flask, and then the following operations were performed: 10 mL of ultra-dry solvent (tetrahydrofuran) was added under argon protection to dissolve the DSPE, followed by 10 μL of freshly evaporated acid-binding agent. The flask was sealed and stirred at room temperature for 24 hours. The reaction solution was then placed in a dialysis bag and dialyzed with ultrapure water for 3 days. The solution was then lyophilized to obtain the final product DSPE-PEG. 2k -6R / RRERRR / RRRYRR (peptide-modified lipid material), the chemical structure of the product was characterized using 1H NMR spectroscopy to verify whether the peptide was successfully coupled to PEG. 2k -DSPE (results shown in Figure 25) combines five lipid components (ionized lipid MC3, phospholipid DSPC, cholesterol, DSPE-PEG) 2k -6R / RRERRR / RRRYRR) were dissolved in ethanol (alcohol phase) at a molar ratio of 50:10:38.5:6:0.75, and Firefly Luciferase mRNA was dissolved in citrate buffer (aqueous phase). The ionized lipids and mRNA were prepared at an N / P ratio of 5.67. The volume ratio of alcohol phase to aqueous phase was 1:3. The alcohol phase and aqueous phase were flowed at a flow rate ratio of 1:3 (0.3 mL / min for alcohol phase and 0.9 mL / min for aqueous phase) through the microfluidic channel shown in Figure 3. The peptide-modified liposomes were collected. Finally, the collected liquid was dialyzed overnight with 1×PBS to obtain peptide-modified liposomes encapsulating Luciferase mRNA.

[0324] 6.1.3 Organ-targeting experiments and results analysis of peptide-modified liposomes

[0325] 6R-LNP, RRERRR-LNP, and RRRYRR-LNP, each encapsulated with Luciferase mRNA, were injected into C57BL / 6J wild-type mice via tail vein injection at a dose of 0.1 mg / kg. Three hours after injection, D-luciferin substrate was injected intraperitoneally at a dose of 100 mg / kg. Five minutes after substrate injection, the mice were euthanized, and major organs (liver, lung, spleen, heart, and kidney) were harvested. Bioluminescence imaging of the excised organs was performed using a small animal in vivo imaging system. In vivo experiments showed that 6R-LNP and RRRYRR-LNP efficiently mediated lung-targeted delivery of Luciferase mRNA, while RRERRR-LNP primarily exhibited liver-targeting activity. Furthermore, the fluorescence signal intensity in the lung region of the RRRYRR-LNP group was significantly higher than that of the 6R-LNP delivery group (results are shown in Figures 26-28).

[0326] 6.1.4 Verification of Prediction Results Based on the Free Energy Theory Model Combined with Vtn

[0327] The binding free energy of 6R (RRRRRR) and its two mutants (RRERRR and RRRYRR) with Vtn was calculated using the method described in Example 5 above. A lower binding free energy (a negative binding free energy indicates a stronger molecular binding) suggests better lung targeting ability. The calculation results show that the ΔG of the RRRRRR and RRRYR sequences... BIND The binding free energy of RRERRR-Vtn is < -30 kcal / mol, and the latter has an even lower binding free energy with Vtn; however, the binding free energy of RRERRR-Vtn is higher than -30 kcal / mol (the results are shown in Figure 29). This indicates that RRERRR and RRRYRR exhibit strong lung targeting, with the latter showing higher delivery efficiency than 6R, while RRERRR does not show lung targeting. This result also demonstrates the accuracy of the lung-targeting peptides predicted by the binding free energy theoretical model.

[0328] 6.1.5 Verification of the prediction results of the energy release rate theoretical model with Vtn

[0329] The energy release rate (G value) of 6R (RRRRRR) and its two mutants (RRRYRR, RRERRR) with Vtn was calculated using the method described in Example 4 above, and the results are shown in Figure 30. The results show that the energy release rate (G) of 6R and RRRYRR peptides with Vtn is... The results of RRERRR did not match, which is consistent with the results of the organ-targeting experiments mentioned above, indicating that the lung-targeting ability of the peptide can also be determined by the G value.

[0330] 6.2 Lung-targeting validation of 3R / 4R / 5R / 6R / 7R / 8R / 9R / 10R peptide sequences

[0331] 6.2.1 Following the experimental method in Example 6.1, nine polypeptides of different sizes, namely 2R (Seq ID No. 7), 3R (Seq ID No. 8), 4R (Seq ID No. 9), 5R (Seq ID No. 10), 6R (Seq ID No. 3), 7R (Seq ID No. 11), 8R (Seq ID No. 12), 9R (Seq ID No. 13), and 10R (Seq ID No. 14), were synthesized and prepared. Here, nR represents Cys-(Arg)n, and n = 2, 3, 4, 5, 6, 7, 8, 9, or 10. The polypeptides were then characterized, and polypeptide-modified liposomes were prepared. The synthesized liposomes were intravenously injected into mice, and the fluorescence intensity of the organs was statistically compared. The statistical results are shown in Figure 31. The results show that the main target organ for 6R is the lung, the target organ for the 3R-modified vector is the liver, and the target organs for 5R are both the liver and lung.

[0332] 6.2.2 Using the methods described in Examples 4 and 5, the energy release rate and binding energy of each peptide with Vtn were calculated (except for Vtn-2R, which could not be modeled by AF3). The results are shown in Figures 32 and 33. The results show that among the binding energy and energy release rate values ​​of each peptide with Vtn, peptide 6R is relatively prominent, satisfying ΔG BIND <-30 kcal / mol, and Other peptides that do not have lung-targeting capabilities do not satisfy the energy relationship with Vtn. This is consistent with the lung-targeting peptide model proposed in this application.

[0333] 6.3 Lung-targeting validation of the DDDDDD\DDEEDD\DDTTDD\DDDDEE\DDDDTT peptide sequence

[0334] Following the experimental method described in Example 6.1, polypeptide sequences DDDDDD (Seq ID No. 15), DDEEDD (Seq ID No. 16), DDTTDD (Seq ID No. 17), DDDDEE (Seq ID No. 18), and DDDDTT (Seq ID No. 19) were synthesized and prepared. The polypeptides were then characterized, and polypeptide-modified liposomes were prepared. The synthesized liposomes were intravenously injected in vivo, and the fluorescence intensity of the organs was statistically compared. The statistical results are shown in Figure 34. The results show that these five polypeptides exhibited significant spleen targeting in the experiment.

[0335] Using the method described in Example 5, the binding free energy of each of the above-mentioned peptides with the target protein Vtn was calculated. The results in Figure 35 show that their binding energies are all greater than -30 kcal / mol, which also verifies that the Δ... GBIND A lung-targeting criterion of <-30 kcal / mol is required.

[0336] The embodiments described above are merely preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Various modifications and improvements made by those skilled in the art to the technical solutions of the present invention without departing from the spirit of the present invention should fall within the protection scope defined by the claims of the present invention.

Claims

1. A polypeptide-modified lipid material, wherein, The peptide-modified lipid material is obtained by coupling a peptide to a lipid material containing a polyethylene glycol chain; The polypeptide is Cys-(X)n, wherein X is any one or both of Lys, His or Arg, and n is the total number of X and is an integer in the range of greater than 1 and less than 11; The polypeptide is coupled to the polyethylene glycol chain via a thiol group on its cysteine ​​residue.

2. The polypeptide-modified lipid material according to claim 1, wherein, Some or all of the n X's are Lys.

3. The polypeptide-modified lipid material according to claim 2, wherein, When some of the n X's are Lys, the rest of the X's are Arg.

4. The polypeptide-modified lipid material according to claim 1, wherein, All n X's are His.

5. The polypeptide-modified lipid material according to any one of claims 2 to 4, wherein n = 2, 3, 4, 5, 6, 7, 8 or 10, preferably n = 3, 4, 5, 6, 7 or 8.

6. The polypeptide-modified lipid material according to claim 1, wherein, The lipid material containing polyethylene glycol chains is Mal-PEG2k-DSPE.

7. The use of the peptide-modified lipid material according to any one of claims 1 to 6 in the preparation of peptide-modified liposomes for targeted drug delivery.

8. The application according to claim 7, wherein, The peptide-modified liposomes used for targeted drug delivery target organs or tissues in vivo, such as the placenta, bone marrow, testes, and / or adipose tissue.

9. A peptide-modified liposome for targeted drug delivery, wherein the raw materials for preparing the peptide-modified liposome include the peptide-modified lipid material according to any one of claims 1 to 6.

10. The polypeptide-modified liposome according to claim 9, wherein, The peptide-modified liposomes also include ionized lipids, phospholipids, cholesterol, and phospholipid-polyethylene glycol.

11. The polypeptide-modified liposome according to claim 10, wherein, The molar ratio of the ionized lipid, the phospholipid, the cholesterol, the polypeptide-modified lipid material, and the phospholipid-polyethylene glycol is (40-60):(5-15):(30-45):(3-12):(0.5-1.5).

12. The polypeptide-modified liposome according to claim 11, wherein, The phospholipid is distearylphosphatidylcholine, 1,2-dioleoyl-SN-glycerol-3-phosphocholine, 1,2-dioleoyltriyl-3-phosphatidylethanolamine, hydrogenated soybean phosphatidylcholine, or lecithin.

13. The polypeptide-modified liposome according to claim 10, wherein, The ionized lipids are MC3, SM102, ALC0315, or LP01.

14. The use of the polypeptide-modified lipid material as described in any one of claims 1 to 6 or the polypeptide-modified liposome as described in any one of claims 9 to 13 in improving drug targeting.

15. The use of the polypeptide-modified lipid material according to any one of claims 1 to 6 or the polypeptide-modified liposome according to any one of claims 9 to 13 in the preparation of a medicament targeting an organ in vivo, wherein the organ or tissue in vivo is the placenta, bone marrow, testis and / or adipose tissue.

16. A method for improving drug targeting, comprising using a peptide-modified lipid material as described in any one of claims 1 to 6 or a peptide-modified liposome as described in any one of claims 9 to 13.

17. A lung-targeting polypeptide sequence, wherein the energy relationship between the polypeptide sequence and vilinkin (Vtn) satisfies the following condition: and / or Binding free energy (ΔG BIND ) < -30 kcal / mol, in, The energy release rate (G) is the energy of breaking the polypeptide sequence and vitronectin binding interface, the binding free energy (AG BIND ) is the sum of the molecular mechanics energy (G GAS ) and the solvation energy (G SOLV ) between the polypeptide sequence and vitronectin.

18. The polypeptide sequence according to claim 17, wherein, The energy release rate (G) is the ratio of the mechanical work (W) of the polypeptide sequence and glassin in the molecular dynamics model to the nominal contact area (S).

19. The polypeptide sequence according to claim 18, wherein, The mechanical work (W) is obtained as follows: A stretching molecular dynamics model of the peptide sequence and polinecin was established. In the complex structure of the peptide and polinecin, the peptide was stretched along the vector direction of the peptide at a constant rate of 1 nm / ns. The vector direction of the peptide was defined as the direction of the line connecting the terminal amino acid of the peptide away from the binding pocket and the starting amino acid of the other end. The area under the force-stretching curve within the displacement range of the peptide being pulled out of the complex structure was calculated by integral calculation, which is the mechanical work (W).

20. The polypeptide sequence according to claim 18, wherein, The nominal contact area (S) is obtained by the following formula: S = n × L × b, Where n is the number of amino acids contained in the polypeptide sequence, L is the average length of each amino acid in the polypeptide sequence, and b is the average width of each amino acid in the polypeptide sequence.

21. The polypeptide sequence according to claim 20, wherein, n is a natural number, preferably selected from 3, 4, 5, 6, 7, 8, 9, 10 or 11.

22. The polypeptide sequence according to claim 17, wherein, The molecular mechanics energy (G GAS ) is derived from the following equation: G GAS = G BOND + G ANGLE + G DIHED + G VDWAALS + G EEL wherein G BOND =SK b (b-b0) 2 ,G ANGLE =SK θ (θ-θ0) 2 ,G DIHED =SK χ (1-cos(nx-δ)), G VDWAALS =In[(R min / r ij ) 12 -(R min / r ij ) 6 ],G EEL =Σq i q j / ε1r ij , b is the covalent bond length, b0 is the equilibrium value, θ is the covalent bond angle, θ0 is the equilibrium value, χ is the dihedral angle, n is the dihedral angle period, δ is the phase angle, and K b K θ K χ R is the force constant, ε is the depth of the Lennard-Jones potential well, and R is the force constant. min r is the distance at the minimum of the Lennard-Jones potential. ij q is the distance between atoms i and j. i q j ε is the atomic charge, and ε1 is the effective dielectric constant.

23. The polypeptide sequence according to claim 17, wherein, The solvation energy (G) SOLV ) is the polar solvation energy (E PB ) and nonpolar solvation energy (E SURF The sum of the polar solvation energies (E) PB The nonpolar solvation energy (E) was calculated using the Poisson-Boltzmann method. SURF )=γ·SASA+β.

24. The polypeptide sequence according to claim 17, wherein, The polypeptide sequence is RRRRRR (Seq ID No. 1) or RRRYRR (Seq ID No. 2).

25. A peptide-modified lipid material with lung-targeting properties, wherein the peptide-modified lipid material is obtained by coupling a peptide to a lipid material containing a polyethylene glycol chain; in, The polypeptide comprises the polypeptide sequence according to any one of claims 17 to 24.

26. The polypeptide-modified lipid material according to claim 25, wherein, One end of the polypeptide is a cysteine ​​residue (Cys), which is coupled to the polyethylene glycol chain.

27. The polypeptide-modified lipid material according to claim 26, wherein, The polypeptide is Cys-X, where X is the polypeptide sequence described in any one of claims 17 to 24.

28. The polypeptide-modified lipid material according to claim 25, wherein, The lipid material containing a polyethylene glycol chain is Mal-PEG 2k -DSPE.

29. A peptide-modified liposome for targeted drug delivery, wherein the raw materials for preparation include the peptide-modified lipid material according to any one of claims 25 to 28.

30. The polypeptide-modified liposome according to claim 29, wherein, The raw materials for preparing the polypeptide-modified liposomes also include ionized lipids, phospholipids, cholesterol, and phospholipid-polyethylene glycol.

31. The polypeptide-modified liposome according to claim 30, wherein, The molar ratio of the ionized lipid, the phospholipid, the cholesterol, the polypeptide-modified lipid material, and the phospholipid-polyethylene glycol is (40-60):(5-15):(30-45):(3-12):(0.5-1.5).

32. The polypeptide-modified liposome according to claim 30, wherein, The phospholipid is distearylphosphatidylcholine, 1,2-dioleoyl-SN-glycerol-3-phosphocholine, 1,2-dioleoyltriyl-3-phosphatidylethanolamine, hydrogenated soybean phosphatidylcholine, or lecithin.

33. The polypeptide-modified liposome according to claim 30, wherein, The ionized lipids are MC3, SM102, ALC0315, or LP01.

34. The use of the polypeptide sequence as described in any one of claims 17 to 24, or the polypeptide-modified lipid material as described in any one of claims 25 to 28, or the polypeptide-modified liposome as described in any one of claims 29 to 33, in the preparation of lung-targeted drug delivery.

35. The use of the polypeptide sequence as described in any one of claims 17 to 24, or the polypeptide-modified lipid material as described in any one of claims 25 to 28, or the polypeptide-modified liposome as described in any one of claims 29 to 33, in improving drug lung targeting.

36. A method for improving drug lung targeting, comprising using a polypeptide sequence as described in any one of claims 17-24, or a polypeptide-modified lipid material as described in any one of claims 25-28, or a polypeptide-modified liposome as described in any one of claims 29-33.

37. A method for screening organ-targeting polypeptide sequences, comprising: The energy relationship between the target polypeptide sequence and the target protein that mediates organ targeting is obtained, and the energy relationship is used to determine whether the target polypeptide sequence has organ targeting specificity. Wherein, the energy relationship refers to the cleavage energy at the binding interface between the target polypeptide sequence and the target protein, expressed as energy release rate (G), and / or the molecular mechanical energy (G0) between the target polypeptide sequence and the target protein. GAS ) and solvation energy (G SOLV The sum of ) to combine the free energy (ΔG) BIND )express.

38. The method according to claim 37, wherein, The energy relationship between the target polypeptide sequence and the target protein mediating organ targeting is obtained. Based on the energy relationship, the target polypeptide sequence is considered to have organ targeting ability if the following conditions are met: and / or Combined free energy (ΔG) BIND <30 kcal / mol Preferably, the organ is the lung, and the target protein is vitrin (Vtn).

39. The method according to claim 37 or 38, wherein, The energy release rate (G) is the ratio of the mechanical work (W) of the polypeptide sequence and the target protein in the molecular dynamics model to the nominal contact area (S).

40. The method according to claim 39, wherein, The mechanical work (W) is obtained as follows: In the complex structure in which the peptide binds to the target protein, the peptide is stretched along its vector direction at a constant rate of 1 nm / ns. The vector direction of the peptide is defined as the direction of the line connecting the terminal amino acid at the end far from the binding pocket and the starting amino acid at the other end. The area under the force-stretch curve within the displacement range of the peptide being pulled out of the complex structure is calculated by integral and is the mechanical work (W).

41. The method according to claim 39, wherein, The nominal contact area (S) is obtained by the following formula: S = n × L × b, Where n is the number of amino acids contained in the polypeptide sequence, L is the average length of each amino acid in the polypeptide sequence, and b is the average width of each amino acid in the polypeptide sequence.

42. The method according to claim 41, wherein, n is selected from 3, 4, 5, 6, 7, or 8.

43. The method according to claim 37 or 38, wherein, The molecular mechanical energy (G) GAS It is derived from the following formula: G GAS = G BOND +G ANGLE +G DIHED +G VDWAALS +G EEL , Among them, G BOND =SK b (b-b0) 2 ,G ANGLE =SK θ (θ-θ0) 2 ,G DIHED =SK χ (1-cos(nx-δ)), G VDWAALS =In[(R min / r ij ) 12 -(R min / r ij ) 6 ],G EEL =Σq i q j / ε1r ij , b is the covalent bond length, b0 is the equilibrium value, θ is the covalent bond angle, θ0 is the equilibrium value, χ is the dihedral angle, n is the dihedral angle period, δ is the phase angle, and K b K θ K χ R is the force constant, ε is the depth of the Lennard-Jones potential well, and R is the force constant. min r is the distance at the minimum of the Lennard-Jones potential. ij q is the distance between atoms i and j. i q j ε is the atomic charge, and ε1 is the effective dielectric constant.

44. The method according to claim 37 or 38, wherein, The solvation energy (G) SOLV ) is the polar solvation energy (E) PB ) and nonpolar solvation energy (E SURF The sum of the polar solvation energies (E) PB The nonpolar solvation energy (E) was calculated using the Poisson-Boltzmann method. SURF )=γ·SASA+β.